Status:
COMPLETED
AZD8529 Single Ascending Dose Study
Lead Sponsor:
AstraZeneca
Conditions:
Healthy Volunteer
Eligibility:
All Genders
18-45 years
Phase:
PHASE1
Brief Summary
This is a study to evaluate safety, tolerability, PK and PD effects of orally administered AZD8529 after single ascending doses
Eligibility Criteria
Inclusion
- Healthy male or female subjects aged 18 to 45 years (inclusive) on Day 1. Female subjects must be of non-child bearing potential.
Exclusion
- Has received another new chemical entity (defined as a compound which has not been approved for marketing) or has participated in any other clinical study that included drug treatment within 3 months of the first administration of investigational prod
- Plasma donation within one month of screening or any blood donation/blood loss \> 500mL during the 3 months prior to screening
- Clinically relevant abnormalities in physical examinations, vital signs, ECG, clinical chemistry, hematology or urinalysis
Key Trial Info
Start Date :
September 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2009
Estimated Enrollment :
58 Patients enrolled
Trial Details
Trial ID
NCT00755378
Start Date
September 1 2008
End Date
March 1 2009
Last Update
March 26 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Philadelphia, Pennsylvania, United States